YourVoice.Now Summary
Average Household ImpactCorporate BenefitsTransparency & AccountabilityDevices FDA calls breakthroughs would get automatic Medicare coverage for four years while CMS decides on permanent coverage.
Average Household Impact
- Medicare coverage — Designated breakthrough devices covered for four years without a national coverage determination
Corporate Benefits
- Coverage pathway for device makers — Medicare must grant designation when the four criteria are met
- Case-by-case coverage review — Set aside for designated devices during the four-year transitional period
Transparency & Accountability
- Reporting requirements — Medicare must report applications, designations and denials to Congress each year
- Reporting requirements — Rejected manufacturers must be told which specific criteria the device failed
The details
Medicare would create a new fast track for medical devices the FDA considers breakthroughs. A manufacturer would apply, and Medicare would have to grant the designation if four tests are met. The device must have received FDA priority review. If it cleared FDA through the 510(k) pathway, that clearance must have rested on clinical data covering Medicare-age patients. The device must be the kind Medicare would otherwise cover. And it must not pose an undue risk of harm that outweighs its benefits. Medicare would decide within six months, and explain in writing which test a rejected device failed. A designated device gets four years of transitional coverage. During that window Medicare pays for it when used as the FDA label directs, without the usual case-by-case judgment about whether it is reasonable and necessary. Medicare must finish a permanent national coverage decision before the four years run out, if asked in time. The bill provides $10 million a year through 2030 to run the program. Medicare could still review providers whose billing for these devices looks out of line with their peers. Designations would start 18 months after enactment.
Congressional Summary
Ensuring Patient Access to Critical Breakthrough Products ActThis bill provides for Medicare coverage of medical devices that are approved under the Food and Drug Administration (FDA) Breakthrough Devices Program. (Under the program, manufacturers work with the FDA to expedite the review and approval of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions.)The bill allows designated medical breakthrough devices to be temporarily covered under Medicare during a four-year transitional period. Manufacturers must apply to the Centers for Medicare & Medicaid Services (CMS) to receive this designation. Qualifying devices must (1) have received priority review from the FDA, (2) received premarket approval (if applicable) based on clinical data that includes data from Medicare beneficiaries, (3) already generally qualify for Medicare coverage, and (4) not present an undue risk of harm that outweighs potential clinical benefits for Medicare beneficiaries.The CMS must approve or deny applications within six months of receipt and must provide an explanation in the case of a denial. In addition, the CMS must make permanent coverage decisions before the end of the transitional period upon a timely request to do so, as specified.The bill provides funds through FY2030 for the CMS to implement the bill.
Legislative Subjects
Details
- Congress
- 119th
- Chamber
- House
- Status
- summarized
- Action
- Introduced in House
- Action Date
- 2025-09-15
- Date Added
- 2026-07-29
- Source
- Congress.gov →
Like reading a bill in plain English?
We're building an app that does this for every bill in Congress and lets you tell your reps how you want them to vote. We're a small team getting ready to launch, and we're trying to show investors that real people want this. Be one of them. Help us get it built. Leave your email and we'll tell you the moment the app is ready.